Regulation of Bcl-2 Expression by Dihydrotestosterone in Hormone Sensitive LNCaP-FGC Prostate Cancer Cells
Abstract
Purpose:
Up-regulation of the anti-apoptotic bcl-2 proto-oncogene is associated with androgen independent prostate cancer progression. This observation suggests that the expression of bcl-2 may be negatively regulated by androgens in prostate cancer cells.
Materials and Methods:
The expression of the proto-oncogene bcl-2 was assessed in the hormone sensitive prostate cancer cell line LNCaP-FGC in the presence and absence of a physiological concentration of 1 nM. dihydrotestosterone (DHT). Sequence analysis of the bcl-2 promoter regions demonstrated the presence of 2 potential androgen response elements. Transient transfections of luciferase reporter constructs containing these potential androgen response elements into LNCaP-FGC cells in the presence and absence of DHT were performed. Steady-state transcripts of bcl-2 were assessed using RNase protection assays.
Results:
Cells cultured in charcoal stripped serum in the presence of DHT resulted in down-regulation of bcl-2 protein. Down-regulation of bcl-2 protein and mRNA by DHT was inhibited by coincubation with the antiandrogen bicalutamide, an agent that competitively inhibits binding of DHT to androgen receptor. Luciferase reporter constructs containing candidate androgen response elements were transrepressed in the presence of DHT. Bcl-2 mRNA was also down-regulated by DHT and this down-regulation could not be abolished by cycloheximide.
Conclusions:
Together these results suggest that the suppression of bcl-2 expression by DHT in hormone sensitive LNCaP-FGC prostate cancer cells occurs directly. In addition, these results provide a possible mechanistic basis for the up-regulation (derepression) of bcl-2 observed in hormone independent prostate cancers.
References
- 1 : Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg1941; 43: 209. Crossref, Google Scholar
- 2 : A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer1977; 40: 2836. Google Scholar
- 3 : Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch B Cell Pathol1973; 13: 87. Google Scholar
- 4 : Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res1992; 52: 6940. Medline, Google Scholar
- 5 : Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res1995; 55: 4438. Google Scholar
- 6 : Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo. Int J Mol Med1998; 1: 953. Google Scholar
- 7 : The impact of bcl-2 and bax deficiency on prostate homeostasis in vivo. Oncogene2000; 19: 2404. Google Scholar
- 8 : Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol1995; 146: 1368. Google Scholar
- 9 : The androgen receptor as a mediator of gene expression and signal transduction pathways. Trends Endocrinol Met1998; 9: 150. Google Scholar
- 10 : Expression of maspin in prostate cells is regulated by a positive est element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci USA1997; 94: 5673. Google Scholar
- 11 : Ligand-independent activation of steroid hormone receptors. J Mol Med1998; 76: 469. Crossref, Medline, Google Scholar
- 12 : Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol1999; 19: 6164. Google Scholar
- 13 : Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene2001; 20: 3880. Google Scholar
- 14 : Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology2001; 142: 2419. Google Scholar
- 15 : Androgen down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology1999; 140: 416. Google Scholar
- 16 : The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors. J Biol Chem1996; 271: 19013. Google Scholar
- 17 : Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells. J Androl1998; 19: 127. Google Scholar
- 18 : bcl-2/bax Ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology1998; 52: 1085. Google Scholar
- 19 : Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligo(deoxy)nucleotides. J Natl Cancer Inst2000; 92: 34. Google Scholar
From the Departments of Molecular Pathology and Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas
